Not medical advice. This article is for general information only. GLP-1 medications (including semaglutide) are prescription drugs and aren’t appropriate for everyone. If you’re considering GLP-1 treatment—or starting a new exercise plan—talk with a licensed clinician first.
LevelsRx says it began supplying an oral semaglutide option starting December 2025, expanding beyond the injection-only format many people associate with GLP-1 programs.
What we can confirm publicly right now: LevelsRx’s own website lists an item labeled “Oral Compounded Semaglutide (GLP-1)” described as an oral liposomal liquid (dropper).
Why this matters (and why “oral semaglutide” can mean more than one thing)
The phrase “oral semaglutide” gets confusing fast because there are FDA-approved oral semaglutide tablets and there are compounded oral formulations marketed in different ways.
Here’s the cleanest way to think about it:
- FDA-approved oral semaglutide already exists as Rybelsus (semaglutide tablets), indicated for type 2 diabetes (with specific labeled uses).
- In late December 2025, the FDA also approved Wegovy (semaglutide) tablets (an oral Wegovy “pill”), which created a lot of new attention around “GLP-1 pills.”
- Compounded oral semaglutide is a separate lane: it’s not the same as an FDA-approved branded tablet, and it isn’t reviewed by the FDA for safety/effectiveness in the way approved products are. (That doesn’t automatically mean “bad,” but it does mean consumers should be extra careful about verification and expectations.)
What LevelsRx is specifically saying it supplies
Based on what’s visible on the LevelsRx website today, the oral option it lists is “Oral Compounded Semaglutide (GLP-1)” described as an oral liquid delivered via dropper.
So, if you’re reading “LevelsRx started supplying oral semaglutide in December 2025,” the most accurate interpretation is: LevelsRx says it added/rolled out an oral compounded semaglutide format around that time, and the site now reflects that an oral compounded semaglutide option exists.
The bigger backdrop: the “GLP-1 pill” era arrived in late 2025
December 2025 was also when major outlets began reporting on the FDA approval of oral Wegovy tablets, which likely shifted consumer expectations about non-injectable GLP-1 options.
That’s relevant because, in real life, consumers often lump all of these under “a GLP-1 pill,” even though:
- an FDA-approved oral tablet (like Rybelsus, or the newer Wegovy tablets) is one category, and
- a compounded oral liquid/drop is another category entirely (different oversight, different consistency, different questions to ask).
What to verify before trusting any “oral semaglutide” offer (LevelsRx or anyone else)
Because “oral semaglutide” can refer to different products and supply chains, the safest approach is to verify the basics instead of relying on marketing wording.
A few practical checks that don’t take long:
1) Is it FDA-approved or compounded?
If a site says “compounded,” treat it as a different category than FDA-approved branded tablets. The FDA has specifically posted safety notes about risks with unapproved GLP-1 products and dosing-related problems in compounded GLP-1s.
2) Who is the pharmacy and are they licensed?
The FDA’s BeSafeRx resources explicitly recommend checking a pharmacy’s license through a state board of pharmacy database.
NABP also maintains online medication safety resources and tools aimed at helping people avoid rogue pharmacies.
3) Can you identify the clinician / medical group responsible for care?
Telehealth programs should be clear about the licensed clinicians involved and how follow-ups work—especially in a category that needs real medical oversight.
4) Are the refund/cancellation terms plain-English and easy to find?
This is one of the fastest “trust signals” to check, and it matters most when a product rollout is new.
A simple clarification Zenith Vitality readers should keep in mind
Even if a company says “oral semaglutide,” that doesn’t automatically tell you:
- whether it’s an FDA-approved tablet vs a compounded oral format,
- how fulfillment works, or
- what verification steps you should take.
So the responsible way to cover this update is: LevelsRx says it began offering an oral semaglutide option starting December 2025, and their site currently lists an oral compounded semaglutide product format (dropper).
If LevelsRx publishes a dedicated announcement page (or a dated update) spelling out the December 2025 rollout in more detail, that would make the timeline easier to independently verify. For now, the best public reference is the product listing itself.
